Abstract

BackgroundMesenchymal stem cells (MSCs) were considered a regenerative therapeutic approach in both acute and chronic diseases. However, whether MSCs regulate the antioxidant metabolism of CD4+ T cells and weaken immunosenescence remains unclear. Here, we reported the protective effects of hPMSCs in aging-related CD4+ T cell senescence and identified the underlying mechanisms using a d-gal-induced mouse aging model.MethodsIn vivo study, 40 male C57BL/6 mice (8 weeks) were randomly divided into four groups: control group, d-gal group, hPMSC group, and PBS group. In in vitro experiment, human naive CD4+ T (CD4CD45RA) cells were prepared using a naive CD4+ T cell isolation kit II and pretreated with the Akt inhibitor LY294002 and Nrf2 inhibitor ML385. Then, isolated naive CD4+ T cell were co-cultured with hPMSCs for 72 h in the absence or presence of anti-CD3/CD28 Dynabeads and IL-2 as a mitogenic stimulus. Intracellular ROS changes were detected by flow cytometry. The activities of the antioxidant enzymes superoxide dismutase, glutathione peroxidase, and catalase were measured by colorimetric analysis. The senescent T cells were detected SA-β-gal stain. The expression of aging-related proteins was detected by Western blotting, RT-PCR, and confocal microscopy.ResultsWe found that hPMSC treatment markedly decreased the ROS level, SA-β-gal-positive cells number, senescence-associated secretory phenotype (IL-6 and OPN) expression, and aging-related protein (P16 and P21) expression in senescent CD4+ T cells. Furthermore, hPMSC treatment effectively upregulated Nrf2 nuclear translocation and the expression of downstream target genes (HO-1, CAT, GCLC, and NQO1) in senescent CD4+ T cells. Moreover, in vitro studies revealed that hPMSCs attenuated CD4+ T cell senescence by upregulating the Akt/GSK-3β/Fyn pathway to activate Nrf2 functions. Conversely, the antioxidant effects of hPMSCs were blocked by the Akt inhibitor LY294002 and Nrf2 inhibitor ML385 in senescent CD4+ T cells.ConclusionsOur results indicate that hPMSCs attenuate d-gal-induced CD4+ T cell senescence by activating Nrf2-mediated antioxidant defenses and that upregulation of Nrf2 by hPMSCs is regulated via the Akt/GSK-3β/Fyn pathway.

Highlights

  • With the aging process, the immune system function gradually declines, leading to alterations in innate and adaptive immunity in older individuals, which is designated “immunosenescence” [1]

  • Our results indicate that hPMSCs attenuate D-gal-induced CD4+ T cell senescence by activating Nrf2mediated antioxidant defenses and that upregulation of Nuclear factor erythroid-2-related factor 2 (Nrf2) by hPMSCs is regulated via the Protein kinase B (Akt)/Glycogen synthase kinase 3β (GSK-3β)/Fyn pathway

  • The reactive oxygen species (ROS) level markedly increased in CD4+ T cells collected from D-gal group compared with the control group, while hPMSC treatment significantly decreased the generation of ROS in comparison with that of the PBS treatment group (Fig. 1b–d)

Read more

Summary

Introduction

The immune system function gradually declines, leading to alterations in innate and adaptive immunity in older individuals, which is designated “immunosenescence” [1]. Immunosenescence affects function and compartment of T cells, leading to age-related immune function decline and increases the susceptibility of elderly individuals to cancers and infectious diseases [2]. There is evidence that activated Nrf protection against the phenotypic changes and mitochondrial function in memory T cells, relieve agedrelated oxidant injury [9]. Increasing evidence suggests that Nrf pathway is essential in regulating the innate immune system function [10]. Together, these data suggest that interfering with Nrf antioxidant signal provides a rational approach to alleviate cellular immune dysfunction during aging. We reported the protective effects of hPMSCs in aging-related CD4+ T cell senescence and identified the underlying mechanisms using a D-gal-induced mouse aging model

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call